Clinical Trial Update: An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM) [Phase 2]

View source ↗

Summary

An open-label extension safety study of MELAS patients who completed the TIS6463-203 (PRIZM) trial is currently enrolling by invitation in Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Encephalopathy Lactic Acidosis and Stroke-like Episodes

Drugs mentioned

• TIS6463 (TIS6463)

Snippet

Sponsor: Tisento Therapeutics | Conditions: Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) | Phase 2 | Status: ENROLLING_BY_INVITATION